Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 2Other solid neoplasm 1

Conditions

Neoplasms 2Malignant Solid Tumors 1

Interventions

Cyclophosphamide 3162Cisplatin 3160Carboplatin 2938Paclitaxel 2673Radiotherapy 2648Gemcitabine 2547pembrolizumab 2331Docetaxel 2157Bevacizumab 2128Fluorouracil 1822Capecitabine 1784Oxaliplatin 1713Dexamethasone 1590Nivolumab 1517Doxorubicin 1477Rituximab 1454Etoposide 1342Magnetic Resonance Spectroscopy 1266Irinotecan 1235Leucovorin 1216Cytarabine 1123Pemetrexed 1062Drug Therapy 1062fludarabine 1050Vincristine 956Specimen Handling 936Prednisone 926Cetuximab 921Lenalidomide 916Trastuzumab 902

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × SAR125844 × Clear all
NCT01391533 2016-04-13

SARMET

Sanofi

Phase 1 Completed
72 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT02435121 2016-03-23

A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification

Sanofi

Phase 2 Completed
1 enrolled
Tumor-Agnostic

Neoplasms

NCT01657214 2016-02-17

SARMETA

Sanofi

Phase 1 Completed
70 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡